NCT06706921 is a Phase 4 clinical trial of 18F-Fluciclovine PET/CT Scan in Prostatic Neoplasms, sponsored by VA Greater Los Angeles Healthcare System.

Who is sponsoring NCT06706921?

NCT06706921 is sponsored by VA Greater Los Angeles Healthcare System.

What drugs are being tested in NCT06706921?

Interventions in NCT06706921: 18F-Fluciclovine PET/CT Scan.

What condition does NCT06706921 study?

NCT06706921 studies Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer, Male Urogenital Diseases, Prostatic Diseases, Urogenital Diseases, Male, Genital Diseases, Male, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Genital Neoplasms, Male.

Is NCT06706921 still recruiting?

NCT06706921 is currently recruiting now. Last updated 27 November 2024.

Last reviewed 2024-11-27 · How we verify

NCT06706921

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

Recruiting now Phase 4 Last updated 27 November 2024

What this trial tests

Phase 4 trial testing 18F-Fluciclovine PET/CT Scan in Prostatic Neoplasms in 15 participants. Currently enrolling.

Timeline

15 December 2024

Primary endpoint
1 November 2027

1 November 2027

Quick facts

Lead sponsor	VA Greater Los Angeles Healthcare System
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	15
Start date	15 December 2024
Primary completion	1 November 2027
Estimated completion	1 November 2027
Sites	1 location across United States

Drugs / interventions tested

18F-Fluciclovine PET/CT Scan — full drug profile →

Conditions studied

Prostatic Neoplasms — all drugs for Prostatic Neoplasms →
Prostatic Neoplasms, Castration-Resistant — all drugs for Prostatic Neoplasms, Castration-Resistant →
Metastatic Prostate Cancer — all drugs for Metastatic Prostate Cancer →
Male Urogenital Diseases — all drugs for Male Urogenital Diseases →

Sponsor

VA Greater Los Angeles Healthcare System — full company profile →

Who can join

18 and older, male only, with Prostatic Neoplasms or Prostatic Neoplasms, Castration-Resistant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA RLT) at the West Los Angeles VA (WLA-VA) will be imaged with a baseline F-18 fluorodeoxyglucose positron emission tomography/computed tomography 18F-FDG PET/CT and a 18F-DCFPyL PET/CT (18F-DCFPyL (2-(3-{1-carboxy-5-\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido)-pentanedioic acid)positron emission tomography/computed tomography , as per standard of care in our institution. All patients further undergo eventual follow-up prostate-specific membrane antigen positron emission tomography (PSMA PET) after the 2nd, 4th, and 6th LuPSMA RLT cycle. In this prospective study, an18F-Fluciclovine positron emission tomography/computed tomography ( Axumin PET/CT )will be additionally obtained at baseline (pre-LuPSMA RLT), and after the 2nd, 4th, 6th LuPSMA RLT cycles. Axumin PET/CT will be acquired within 7 days from the PSMA PET. This study is open to Veterans only.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Prostatic Neoplasms

Currently open trials in the same condition.

NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
NCT06547398 — Prostate Adaptive Radiation Therapy · NA · recruiting

Other VA Greater Los Angeles Healthcare System trials

Trials by the same sponsor.

NCT07031245 — Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout · NA · recruiting
NCT06932289 — Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions · NA · not yet recruiting
NCT06039865 — Chronic Care Management With Wearable Devices in Patients Prescribed Positive Airway Pressure Therapy (mPAP) Trial · NA · completed
NCT05820724 — PSMA PET Scan and mpMRI for Prostate Cancer Detection · Phase 2 · not yet recruiting
NCT05001165 — Dashboard Activated Services and Tele-Health for Heart Failure · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06706921 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by VA Greater Los Angeles Healthcare System
Last refreshed: 27 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06706921.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing